Future work will incorporate more comprehensive cognitive assessments—including measures of memory, executive function, and language—to better characterize cognitive profiles across groups since our study was focused specifically on differences in AD biomarker expression by race/ethnicity and APOE4 status, independent of cognitive performance. This evidence concerns the gene APOE and Alzheimer disease.